Through pediatric and adult perspectives, this program will review the genetics, diagnosis, and management of PFIC and Alagille syndrome, providing practical insights to support care across pediatrics and adults and helping clinicians navigate management considerations.
Industry Supporter: Ipsen
MASLD arises within systemic metabolic dysfunction, but what determines progression to MASH and fibrosis within the liver? This program examines how hepatic metabolic adaptation can become maladaptive under persistent stress, triggering cellular injury, inflammatory signaling, and fibrogenesis that drive progressive liver disease.
Industry Supporter: Madrigal
On May 15-16, 2027, at Digestive Disease Week® (DDW), join AASLD faculty as they explore how cellular senescence contributes to...
Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center
(MSK), Professor of Medicine at Weill Medical School at Cornell University, and Adjunct
Professor at Trinity College Dublin in Dublin, Ireland.
Professor Abou-Alfa majored in biology, earned his medical degree, and now serves as a trustee
on the Board of Trustees of his alma mater the American University in Beirut (AUB). Professor
Abou-Alfa completed his postdoctoral training in internal medicine, medical oncology, and
Dr. Anita Kohli is a board-certified infectious disease specialist and CEO and Director of Clinical Research at Arizona Liver Health and Arizona Clinical Trials. Dr. Kohli has over 18 years of experience in the field of liver disease, treats viral hepatitis and MASH, and leads much of the country's cutting-edge research in liver disease. She is a nationally and internationally recognized expert in clinical and transitional research and has been the lead/principal investigator in multiple studies on various liver conditions. Dr.
Jörn M. Schattenberg is a Professor of Medicine and Director of the Department of Medicine II at the Saarland University Medical Center in Homburg and the University of the Saarland in Germany. He received his medical degree in 2002 after studying at the University of Mainz (Germany) and at the Tulane University in New Orleans (US).
Manal F. Abdelmalek, MD, MPH, FAASLD is a Professor of Medicine, Director of the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Clinical Research Program at Mayo Clinic, Rochester, Minnesota. Her clinical and research area of interest has focused on NAFLD / NASH, associated risk factors for disease acquisition and progression and the discovery of novel approaches to treatment.
Chari Cohen is President of the Hepatitis B Foundation. She conducts research and implements programs to reduce health disparities and improve health outcomes associated with hepatitis B, hepatitis D and liver cancer. Dr. Cohen is co-chair of the Hep B United coalition, co-founder and chair of Hep B United Philadelphia, co-founder and chair of CHIPO: Coalition Against Hepatitis for People of African Origin; and former co-chair of the Hep Free PA coalition.
Michael R Stinchon, Jr, RPh, is the Associate Director of Government Programs- Formulary Strategy and Trend Management for Optum Rx in Avon, Connecticut. He has an extensive background in managed care working as a clinical consultant for several lines of business including Commercial, Medicaid, and Medicare. Previously, he was the Director of Specialty Programs for Aetna Medicaid and Clinical Director of Pharmacy at Bright Health. Mr Stinchon received his bachelor's degree in pharmacy from the University of Connecticut in Storrs.
Dr. Yasmin Ibrahim is a Senior Public Health Program Director at the Hepatitis B Foundation (HBF), where
she leads the Patient Engagement Program. Her work focuses on assessing patient-reported outcomes
(PROs) and quality of life (QoL) among people living with hepatitis B and delta to ensure that care and
treatment reflect outcomes that matter most to patients.
She collaborates with global advocates and scientific experts to integrate patient perspectives into clinical